Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support of SiranBio’s Dual-Target siRNA Program

5 May 2026 -- Singapore, Singapore -- Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end development and manufacturing solutions for structurally complex oligonucleotide therapeutics.

Hongene supported the SA1211 program with vertically integrated CDMO services spanning raw materials production, process development, analytical development, cGMP drug substance and drug product manufacturing, and regulatory and CMC support.

The program reflects the increasing complexity of next-generation siRNA therapeutics and highlights the importance of strong capabilities in synthesis, impurity control, scale-up, and clinical-stage manufacturing.

“Programs like SA1211 show where the field is heading,” said Dr. David Butler, Chief Technology Officer at Hongene. “As siRNA designs become more complex, the bar for development and CMC execution rises with them. Our role is to give customers the technical depth and manufacturing flexibility to move these molecules forward with confidence.”

Dr. Butler added, “While SA1211 was manufactured using traditional solid-phase oligonucleotide synthesis, we are already applying our chemoenzymatic ligation platform to other complex dual-targeting siRNA programs in development. For next-generation constructs, we expect ligation to provide a highly attractive route to modular, high-purity, and scalable manufacturing.”

The SA1211 program further reinforces Hongene’s position as a specialized CDMO partner for innovative oligonucleotide therapeutics, particularly where molecular complexity and manufacturing execution are critical to program success.

About Hongene
Hongene Biotech is a global RNA technology provider and CDMO, specializing in the design, synthesis, and large-scale manufacture of high-purity nucleic acid raw materials and therapeutics. Founded in 1998 and incorporated in Singapore, the company brings nearly 30 years of RNA-focused expertise to support biotech and pharmaceutical partners worldwide. Visit: hongene.com.

About SiranBio
Founded in May 2022 in Suzhou Industrial Park, SiranBio is a biotechnology company dedicated to the development of innovative siRNA drugs. Co-founded by a team of top scientists and industrialization experts in the nucleic acid therapy field, the company has been recognized as a Suzhou Industrial Park Leading Enterprise and Gusu Leading Enterprise. SiranBio has established an industry-leading nucleic acid drug technology platform with independent intellectual property rights, including eSAFE chemical modification technology, the Stork-W dual-target platform, and intrahepatic/extrahepatic delivery platform technologies. Based on these advanced platforms, the company has built a pipeline of nucleic acid drugs targeting antiviral, cardiovascular, and metabolic diseases, and has entered into multiple out-licensing and R&D cooperation agreements with renowned domestic and international pharmaceutical companies. Visit: siranbio.com/en.